Sickle cell disease due to HBB rs334

For HBB c.20A>T (p.Glu7Val), the causal variant of sickle cell disease, crizanlizumab (Adakveo, Novartis) is a humanized anti-P-selectin monoclonal antibody that reduces vaso-occlusive crises (VOCs) by blocking the adhesion cascade that drives sickle cell vaso-occlusion. P-selectin is upregulated on activated endothelium and platelets in SCD, mediating adhesion of sickled red blood cells, neutrophils, and platelets to the vascular wall — the initiating event in VOC. Crizanlizumab received FDA accelerated approval in November 2019 based on the Phase 2 SUSTAIN trial (PMID: 27959701), which showed 45% reduction in annual VOC rate (1.63 vs 2.98 events/year). Unlike curative approaches (Casgevy, Zynteglo, HSCT), crizanlizumab is a disease-modifying therapy that addresses the downstream vascular pathology without correcting the underlying hemoglobin defect.

The SUSTAIN Phase 2 trial (Ataga et al., 2017, PMID: 27959701, NEJM) randomized 198 SCD patients (HbSS and HbS-beta0 thalassemia) to crizanlizumab 5 mg/kg, 2.5 mg/kg, or placebo IV every 4 weeks. The 5 mg/kg arm showed 45.3% reduction in median annual VOC rate (p=0.01), with 35.8% of patients experiencing zero VOCs during the study. Time to first VOC was significantly delayed (4.07 vs 1.38 months). The confirmatory Phase 3 STAND trial, however, did not meet its primary endpoint of annualized rate of VOCs leading to healthcare visits, and Novartis voluntarily withdrew crizanlizumab from the US market in 2024 — though it remains available in some regions. The mechanism is well-validated: P-selectin blockade disrupts the multicellular adhesion cascade (endothelium-neutrophil-RBC-platelet aggregates) that is central to vaso-occlusion. The anti-adhesion approach is complementary to HbF induction (hydroxyurea), anti-sickling therapies (voxelotor), and curative gene therapy/editing.

The Phase 3 STAND trial failure and subsequent US market withdrawal significantly undermine the clinical evidence base for crizanlizumab. While SUSTAIN showed benefit, the inability to replicate this in STAND raises questions about the magnitude and consistency of the therapeutic effect. Crizanlizumab addresses only one pathological mechanism (adhesion) in a multifactorial disease — sickling itself, hemolysis, inflammation, and vasculopathy all contribute to SCD morbidity. Monthly IV infusions are required indefinitely, creating access and adherence challenges, particularly in low-resource settings where SCD prevalence is highest (sub-Saharan Africa, India). In the context of now-available curative options — Casgevy (CRISPR BCL11A editing) and Zynteglo (lentiviral beta-globin gene addition), both FDA-approved in 2023 — the role of antibody therapy is increasingly as a bridge or alternative for patients who are not candidates for or cannot access curative treatment. Cost (approximately $100,000/year) and the need for IV administration limit global applicability.

CRISPR-Cas9-mediated disruption of the BCL11A erythroid-specific enhancer in autologous CD34+ HSPCs has demonstrated durable reactivation of fetal hemoglobin (HbF) and near-elimination of vaso-occlusive crises in patients homozygous for HBB c.20A>T (p.Glu7Val). Exagamglogene autotemcel (exa-cel/Casgevy) received FDA and MHRA approval in late 2023, representing the first approved CRISPR-based gene editing therapy for any disease.

The pivotal CLIMB-121 trial enrolled patients with severe sickle cell disease (≥2 vaso-occlusive crises/year). At 12+ months follow-up, 29 of 30 evaluable patients were free of VOCs, with sustained HbF levels >20% (mean ~40%). Edited CD34+ cells showed >80% allelic editing at the BCL11A enhancer. The mechanism bypasses the pathogenic HBB variant entirely by reactivating gamma-globin expression, which inhibits HbS polymerization. ClinVar classifies the c.20A>T variant (VCV000446735) as pathogenic with expert panel review. FDA approved exa-cel (Casgevy) in December 2023 under priority review.

Therapy requires myeloablative busulfan conditioning prior to infusion of edited cells, carrying significant toxicity including prolonged cytopenia and infertility risk. Long-term durability beyond 3-4 years is still being characterized. Off-target editing at the BCL11A locus has been assessed by GUIDE-seq and Digenome-seq but genome-wide off-target effects in engrafted cells require longer follow-up. Cost and manufacturing complexity limit accessibility in sub-Saharan Africa where SCD burden is highest. Patients with organ damage from prior crises may have limited benefit from HbF reactivation alone.

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Sickle cell disease due to HBB rs334 targeting the HBB c.79G>A (p.Glu27Lys) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct the HBB rs334 sickle mutation in autologous HSCs to eliminate sickling and related complications. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: HBB NM_000518.5(HBB):c.79G>A (p.Glu27Lys) is classified as Pathogenic (ClinVar variation ID 3777010). Molecular consequence: missense variant. Protein change: E27K, V24F. 2. Epidemiology: Autosomal recessive hemoglobinopathy prevalent in individuals of African, Middle Eastern, and Indian descent; A allele frequency ~0.10 in African ancestries (BIOMNI-08). 3. Standard of care: Hydroxyurea, chronic transfusions with iron chelation, small molecules (voxelotor, crizanlizumab), and allogeneic HSCT as curative option but limited by donor availability and transplant risks (PAPER-01, PAPER-10, WEB-05). 4. Pipeline: Ex vivo gene-addition (betibeglogene autotemcel) and gene-editing therapies (exa-cel targeting BCL11A enhancer) have reached Phase III / BLA and regulatory review, demonstrating high rates of VOC/transfusion elimination (WEB-04, WEB-05, PAPER-03, PAPER-07, PAPER-08). 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting HBB c.79G>A (p.Glu27Lys) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.

CRISPR-Cas9-mediated disruption of the BCL11A erythroid-specific enhancer in autologous CD34+ HSPCs reactivates fetal hemoglobin (HbF) and has achieved near-complete elimination of vaso-occlusive crises in sickle cell disease patients homozygous for HBB c.20A>T (p.Glu7Val). Exagamglogene autotemcel (exa-cel/Casgevy) received FDA approval in December 2023 and MHRA approval in November 2023, becoming the first CRISPR-based therapy approved for any human disease.

The pivotal CLIMB-121 trial (NCT03745287, completed) enrolled patients with severe SCD (≥2 VOC/year). Published results in the New England Journal of Medicine (PMID:38661449) demonstrated that 29 of 30 evaluable patients were free of vaso-occlusive crises at 12+ months, with sustained HbF >20%% (mean ~40%%). The approach edits the BCL11A erythroid enhancer rather than correcting the HBB variant directly, bypassing the pathogenic p.Glu7Val mutation by reactivating gamma-globin. ClinVar classifies this variant (VCV000446735) as pathogenic with expert panel review. A pediatric trial (NCT05329649) is active but not yet recruiting. Longer-term follow-up study NCT04208529 is ongoing.

Therapy requires myeloablative busulfan conditioning, which carries significant toxicity including prolonged cytopenias, mucositis, hepatic sinusoidal obstruction syndrome, and gonadotoxicity/infertility risk. Off-target editing has been assessed by GUIDE-seq and Digenome-seq, but genome-wide off-target effects in long-term engrafted cells need continued monitoring. Durability beyond 3-4 years is still being characterized. The cost (~$2.2M per treatment) and manufacturing complexity (autologous ex vivo editing requiring apheresis, GMP manufacturing, and cryopreservation) severely limit accessibility in sub-Saharan Africa where >75%% of the global SCD burden exists. Patients with pre-existing end-organ damage may have limited benefit from HbF reactivation alone.